LON:VER Vernalis (VER) Share Price, News & Analysis GBX 6.17 0.00 (0.00%) (As of 10/10/2018) Add Compare Share Share Stock Analysis Stock Analysis About Vernalis Stock (LON:VER) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vernalis alerts:Sign Up Key Stats Today's Range 6.17▼ 6.1750-Day Range 6.17▼ 6.1752-Week Range 2.80▼ 14Volume11,076 shsAverage Volume1.22 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewVernalis plc, a commercial stage pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company markets Tuzistra XR for the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of amoxicillin antibiotic for the treatment of tonsillitis and pharyngitis secondary to streptococcus pyogenes in adults and pediatric patients; and frovatriptan for the acute treatment of migraine. It is also has licensing agreement to develop and commercialize various products focused on the U.S. prescription cough-cold market. In addition, the company is developing V158866, a fatty acid amide hydrolase inhibitor for the treatment of pain; CPI-444, an adenosine A2A receptor antagonist, which is in Phase I/Ib clinical trial to treat patients with various solid tumors; and AUY922, an intravenous Hsp90 inhibitor for treating cancer, as well as CHR2797, an oral aminopeptidase inhibitor for acute myeloid leukemia and myelodysplastic syndrome under Phase II trial. Further, it is developing S55746, a selective Bcl-2 inhibitor that is in Phase I study for the treatment of cancer; V158411 molecule; and RPL554, a novel long-acting inhibitor under Phase II clinical trial for treating inflammatory respiratory diseases. The company has collaborations with Asahi Kasei Pharma; Endo Pharmaceuticals Inc.; Biogen Idec; Lundbeck A/S; Menarini International Operations Luxembourg SA; Novartis Institute for Biomedical Research Inc.; Novartis Pharma AG; Servier Research Group; GlaxoSmithKline plc; Genentech; and Tris Pharma Inc. Vernalis plc was incorporated in 1988 and is headquartered in Winnersh, the United Kingdom.Read More… 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Receive VER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vernalis and its competitors with MarketBeat's FREE daily newsletter. Email Address VER Stock News HeadlinesMestag Therapeutics Ltd.: Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General CounselNovember 13, 2024 | finanznachrichten.deMestag Therapeutics Expands Leadership Team and Appoints Head of Development and General CounselNovember 13, 2024 | markets.businessinsider.com📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.November 21, 2024 | Behind the Markets (Ad)How to grow witch hazel in pots – for long-lasting aromatic flowers during the winter monthsOctober 28, 2024 | msn.comMajor delays on Highway 132 near Vernalis after reports of crashOctober 10, 2024 | msn.comInnovative B7-H3 Inhibitors Set to Transform Cancer Treatment Landscape | DelveInsightOctober 7, 2024 | finance.yahoo.comDoctor charged in connection with Matthew Perry’s death expected to plead guiltyOctober 3, 2024 | ca.news.yahoo.comInterstate 5 closure will delay traffic on westbound 132 & highway in west Stanislaus CountyOctober 2, 2024 | yahoo.comSee More Headlines VER Stock Analysis - Frequently Asked Questions How have VER shares performed this year? Vernalis' stock was trading at GBX 6.17 at the beginning of the year. Since then, VER stock has increased by 0.0% and is now trading at GBX 6.17. View the best growth stocks for 2024 here. How were Vernalis' earnings last quarter? Vernalis plc (LON:VER) announced its quarterly earnings data on Tuesday, September, 12th. The company reported ($4.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.50) by $0.40. The company had revenue of $20.79 million for the quarter. How do I buy shares of Vernalis? Shares of VER stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Vernalis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vernalis investors own include Lloyds Banking Group (LLOY), Filtronic (FTC), BP (BP), Citius Pharmaceuticals (CTXR), Eurasia Mining (EUA), Entain PLC (GVC.L) (GVC) and Herbalife (HLF). Company Calendar Last Earnings9/12/2017Today11/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:VER CUSIPN/A CIKN/A Webwww.vernalis.com Phone+44-118-9380000FaxN/AEmployees350Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (LON:VER) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vernalis plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vernalis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.